Peptides play important roles in human physiology. They present as intact peptides or can arise from protein degradation. Regardless of the source, peptidomics—the characterization of intact peptides in a biological sample—is fast emerging as an approach to uncover another layer in human health and disease.
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Paradigm4, an integrated scientific data analytics company, has launched flexFS, its elastic cloud file system for flexible and more resource-efficient data storage and scalable computing.
